journal article·2025-07-16Open access

Hybrid Aptamer Molecularly Imprinted Polymer Nanoparticles for Reducing Oxidized Low-Density Lipoprotein Internalization by Macrophages

Suticha Chunta, Soemwit Khongwichit, Piyawut Swangphon, Maliwan Srisuk, Peter A. Lieberzeit, Maliwan Amatatongchai

ACS Applied Materials & Interfaces· Volume 17· Issue 28

Abstract

High Resolution Image Download MS PowerPoint Slide Oxidized low-density lipoprotein (oxLDL) is the most typical physiological trigger for the formation of macrophage foam cells, leading to atherosclerosis and coronary heart disease. The inhibition of internalized oxLDL in macrophages is a proven effective strategy for the prevention of atherosclerosis. A hybrid aptamer-molecularly imprinted polymer nanoparticle (AP-MIP NP) is a novel synthetic, biocompatible, selective material that can bind directly to oxLDL and decrease its uptake by macrophages by 62 ± 2% compared to oxLDL alone at a concentration of 8.25 × 10 7 particles/mL. Oil red O staining indicates that macrophages treated with a combination of AP-MIP NP and oxLDL exhibited a marked decrease in intracellular lipid accumulation compared to those treated with oxLDL alone, resulting in reduced foam cell formation and a decrease in the production of tumor necrosis factor-α and interleukin-6 inflammatory cytokines. The polymer nanoparticle matrix effectively serves as a protective shell for the aptamer at hazardous pH conditions of 4.0 and 10.0, as well as in the presence of DNase I at 100 Kunitz units. The AP-MIP NP bound to the oxLDL surface disrupts the interaction between oxLDL and the lectin-like oxLDL receptor-1 and the cluster of differentiation 36 scavenger receptors, as demonstrated by receptor-coupled ELISA. This restricts the ability of macrophages to uptake oxLDL. This hybrid AP-MIP NP shows promise as a future therapeutic agent to reduce oxLDL uptake and inhibit foam cell formation for atherosclerosis prevention.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · Inflammatory Biomarkers in Disease Prognosis · Cholesterol and Lipid Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Medical Technology

Prince of Songkla University

Division of Biological Science, Faculty of Science

Faculty for Chemistry, Department of Physical Chemistry

University of Vienna

Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science

Ubon Ratchathani University

Funding

National Research Council of Thailand · Prince of Songkla University · Graduate School, Prince of Songkla University · Faculty of Science, Prince of Songkla University · ASEAN-European Academic University Network · Bundesministerium für Bildung, Wissenschaft und Forschung · OeAD-GmbH

References (49)

Show source-provided references
1. 10.3389/fphar.2020.61378010.3389/fphar.2020.613780 ↗
2. 10.1016/S0098-2997(00)00005-410.1016/S0098-2997(00)00005-4 ↗
3. 10.1007/s11033-021-07039-910.1007/s11033-021-07039-9 ↗
4. 10.3390/plants1206121410.3390/plants12061214 ↗
5. 10.1016/j.foodchem.2013.06.00310.1016/j.foodchem.2013.06.003 ↗
6. 10.1194/jlr.M02447110.1194/jlr.M024471 ↗
7. 10.1021/np200696r10.1021/np200696r ↗
8. 10.3389/fphar.2017.0037510.3389/fphar.2017.00375 ↗
9. 10.3390/ijms2403205710.3390/ijms24032057 ↗
10. 10.3389/fphys.2020.0095610.3389/fphys.2020.00956 ↗
11. 10.1021/jf903244310.1021/jf9032443 ↗
12. 10.1016/j.atherosclerosis.2012.05.00610.1016/j.atherosclerosis.2012.05.006 ↗
13. 10.1016/j.jff.2022.10525310.1016/j.jff.2022.105253 ↗
14. 10.1016/j.jacc.2011.07.01710.1016/j.jacc.2011.07.017 ↗
15. 10.1016/j.snb.2014.09.09410.1016/j.snb.2014.09.094 ↗
16. 10.3390/nano1111309110.3390/nano11113091 ↗
17. 10.1088/0957-4484/20/16/16560110.1088/0957-4484/20/16/165601 ↗
18. 10.1039/D0CC01325K10.1039/D0CC01325K ↗
19. 10.1021/ja102148f10.1021/ja102148f ↗
20. 10.1002/anie.20191037310.1002/anie.201910373 ↗
21. 10.1002/anie.20190486010.1002/anie.201904860 ↗
22. 10.1074/jbc.M113.53258010.1074/jbc.M113.532580 ↗
23. 10.1074/jbc.M40803720010.1074/jbc.M408037200 ↗
24. 10.1093/nar/19.17.469510.1093/nar/19.17.4695 ↗
25. 10.1021/acsami.0c0575010.1021/acsami.0c05750 ↗
26. Cosmi B. · Curr. Opin. Mol. Ther. · 2009 · 11 · 322
27. 10.1089/nat.2018.075310.1089/nat.2018.0753 ↗
28. 10.1021/acsami.6b0046110.1021/acsami.6b00461 ↗
29. 10.1039/C5BM00341E10.1039/C5BM00341E ↗
30. 10.1039/D4TB02475C10.1039/D4TB02475C ↗
31. 10.1002/gch2.20220021510.1002/gch2.202200215 ↗
32. 10.1039/C9RA07570D10.1039/C9RA07570D ↗
33. 10.1016/j.compbiomed.2024.10899410.1016/j.compbiomed.2024.108994 ↗
34. 10.1016/j.aca.2020.04.01710.1016/j.aca.2020.04.017 ↗
35. 10.1016/j.talanta.2025.12760510.1016/j.talanta.2025.127605 ↗
36. 10.1002/jmr.116310.1002/jmr.1163 ↗
37. 10.1039/C9RA05009D10.1039/C9RA05009D ↗
38. 10.1007/s00216-021-03771-010.1007/s00216-021-03771-0 ↗
39. 10.2147/DDDT.S23301310.2147/DDDT.S233013 ↗
40. 10.1021/acsabm.4c0143210.1021/acsabm.4c01432 ↗
41. 10.1016/j.cyto.2012.02.01010.1016/j.cyto.2012.02.010 ↗
42. 10.3390/ijms2205252910.3390/ijms22052529 ↗
43. 10.1159/00053579310.1159/000535793 ↗
44. 10.1074/jbc.M20592420010.1074/jbc.M205924200 ↗
45. 10.3390/ph1103008010.3390/ph11030080 ↗
46. 10.1002/adma.20140423510.1002/adma.201404235 ↗
47. 10.3390/ph1802017610.3390/ph18020176 ↗
48. 10.1021/mp500329z10.1021/mp500329z ↗
49. 10.1021/acsnano.3c0392510.1021/acsnano.3c03925 ↗